DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for depression with anxiety
News | 04. 17. 2008
BrainCells
SAN DIEGO, April 17, 2008 – BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.
